Preliminary study on the mechanism of L1CAM promoting invasion and metastasis of cervical cancer

  • Suyi Yi *
  • Minjian Wang
  • Yue Zeng
  • Wenting Wu
  • Jing Li
Article ID: 4626
DOI: https://doi.org/10.18282/po4626
Keywords: cell adhesion molecule L1 gene; cervical cancer; tumor cell proliferation; migration; invasion; apoptosis; mRNA expression level

Abstract

Objective To explore the presentational characteristics of cell adhesion molecule L1 gene (L1CAM) in cervical cancer and its bidirectional regulation of tumor cell proliferation, migration, invasion and apoptosis. Methods The mRNA expression level of L1CAM was detected in cervical cancer cell lines (HeLa, SiHa, C-33A) and normal cervical epithelial cells (HcerEpic) using Quantitative Polymerase Chain Reaction (qPCR), and L1CAM expression was regulated us - ing siRNA knockdown and plasmid overexpression techniques. Combined with Western Blot (WB) to verify the efficiency of gene manipulation, CCK-8 assay was used to scout cell proliferation viability, Transwell assay to assess migration and invasion ability, and flow cytometry to analyze the apoptosis rate. Results L1CAM had a relatively higher expression level in the Hela, C-33A than other cervical cell lines. After knocking down L1CAM by siRNA, the proliferative, migratory and invasive capacities of cervical cancer cells were significantly re - duced, the apoptosis rate was markedly increased. Conversely, overexpression of L1CAM significantly enhanced cellular proliferation, migration and invasion while suppressing apoptosis. . Conclusion L1CAM is aberrantly expressed in cervical cancer and has the potential for bi-directional regulation of oncogenic processes, which promotes tumor progression by enhancing proliferation, migra - tion, invasion and inhibiting apoptosis, and targeting L1CAM may provide a new strategy for the treatment of cervical cancer.
Published
2025-08-26

Copyright (c) 2025 Suyi Yi, Minjian Wang, Yue Zeng, Wenting Wu, Jing Li

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

1. Huang, J., Deng, Y., Boakye, D., Tin, M. S., Lok, V., Zhang, L., ... & NCD Global Health Research Group. (2022). Global distribution, risk factors, and recent trends for cervical cancer: a worldwide country-level analysis. Gy-necologic oncology, 164(1), 85-92.

2. Wilailak, S., Kengsakul, M., & Kehoe, S. (2021). Worldwide initiatives to eliminate cervical cancer. International Journal of Gynecology & Obstetrics, 155, 102-106.

3. Mayadev, J. S., Ke, G., Mahantshetty, U., Pereira, M. D., Tarnawski, R., & Toita, T. (2022). Global challenges of radiotherapy for the treatment of locally advanced cervical cancer. International Journal of Gynecological Cancer. 32(3)，436-445.

4. Guimarães, Y. M., Godoy, L. R., Longatto-Filho, A., & Reis, R. D. (2022). Management of early-stage cervical cancer: a literature review. Cancers, 14(3), 575.

5. Wu, J. S., Jiang, J., Chen, B. J., Wang, K., Tang, Y. L., & Liang, X. H. (2021). Plasticity of cancer cell invasion: Patterns and mechanisms. Translational oncology, 14(1), 100899.

6. Datta, A., Deng, S., Gopal, V., Yap, K. C. H., Halim, C. E., Lye, M. L., ... & Yap, C. T. (2021). Cytoskeletal dynamics in epithelial-mesenchymal transition: insights into therapeutic targets for cancer metastasis. Cancers, 13(8), 1882.

7. Karoii, D. H., Azizi, H., & Amirian, M. (2022). Signaling pathways and protein–protein interaction of vimentin in invasive and migration cells: A review. Cellular Reprogramming, 24(4), 165-174.

8. Schrevel, M., Corver, W. E., Vegter, M. E., Ter Haar, N. T., Dreef, E. J., Beltman, J. J., & Jordanova ES. (2017). L1 cell adhesion molecule (L1CAM) is a strong predictor for locoregional recurrences in cervical cancer. Oncotarget, 18;8(50):87568-87581.

9. Mancusi de Carvalho, J. P., Salim, R. C., Carvalho, F. M., Nogueira Dias Genta, M. L., Baracat, E. C., Carval-ho, J. P. (2020). L1 cell adhesion molecule (L1CAM) in stage IB cervical cancer: distinct expression in squamous cell carcinomas and adenocarcinomas. Journal of Clinical Pathology, 73(11):748-753.[10] Zhang, J., Guo, Z., Xie, Q., Zhong, C., Gao, X., & Yang, Q. (2022). Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway. BMC cancer, 22(1), 457.

10. Pandey, P., Khan, F., Seifeldin, S. A., Alshaghdali, K., Siddiqui, S., Abdelwadoud, M. E., ... & Saeed, A. (2023). Targeting Wnt/β-catenin pathway by flavonoids: implication for cancer therapeutics. Nutrients, 15(9), 2088.

11. Zhu, Y., & Li, X. (2023). Advances of Wnt signalling pathway in colorectal cancer. Cells, 12(3), 447.

12. Li, R. F., Nan, G. X., Wang, D., Gao, C., Yang, J., & Zhang, Z. L. (2021). BMP9 Can Induce Schwann Cells Expressing Simian Virus 40 T Antigen to Differentiate into Fat and Bone In Vivo and In Vitro. Cellular Reprogramming, 23(2), 108-116.

13. Liu, X., Min, S., Wu, N., Liu, H., Wang, T., Li, W., & Wang, X. (2025). miR-193a-3p inhibition of the Slug activator PAK4 suppresses non-small cell lung cancer aggressiveness via the p53/Slug/L1CAM pathway. Cancer Let-ters, 10:447:56-65.

14. Han, C., Sun, L., Pan, Q., Sun, Y., Wang, W., & Chen, Y. (2022). Polysome profiling followed by quantitative PCR for identifying potential micropeptide encoding long non-coding RNAs in suspension cell lines. STAR protocols, 3(1), 101037.

15. Altevogt, P., Doberstein, K., & Fogel, M. (2016). L1CAM in human cancer. International Journal Of Cancer, 138(7):1565-76.

16. Guo, M., Gong, H., Nie, D., & Li, Z. (2021). High L1CAM expression predicts poor prognosis of patients with endometrial cancer: A systematic review and meta-analysis. Medicine, 100(13), e25330.

17. Park, S., Cho, Y., & Kim, H. S. (2023). Mesonephric-like adenocarcinoma of the uterine corpus: Clinico-pathological and prognostic significance of L1 cell adhesion molecule (L1CAM) over-expression. Anticancer Research, 43(10), 4559-4571.

18. Stoyanova, I. I., & Lutz, D. (2022). Functional diversity of neuronal cell adhesion and recognition molecule L1CAM through proteolytic cleavage. Cells, 11(19), 3085.

19. Kiefel, H., Bondong, S., Hazin, J., Ridinger, J., Schirmer, U., Riedle, S., & Altevogt, P. (2012). L1CAM: a major driver for tumor cell invasion and motility. Cell Adhesion & Migration, 6(4):374-84.

20. Shtutman, M., Levina, E., Ohouo, P., Baig, M., & Roninson, I.B. (2006) Cell adhesion molecule L1 disrupts E-cadherin containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Research, 66:11370-80.

21. Riedle, S., Kiefel, H., Gast, D., Bondong, S., Wolterink, S., Gutwein, P., & Altevogt, P. (2009). Nuclear trans-location and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/gamma-secretase activ-ity. Biochemical Journal, 420(3):391-402.

22. Zhang, L. Y., Shen, Z. X., & Guo, L. (2022). Inhibiting L1CAM reverses cisplatin resistance of triple negative breast cancer cells by blocking AKT signaling pathway. Cancer Investigation, 40(4), 313-324.

23. Todorov, T. Z., Schibli, R., Béhé, M., & Grünberg, J. (2024). Targeting Cancer Stem Cells with Radioimmu-notherapy: The Case of the Ovarian Cancer Stemness-Associated Biomarker L1CAM. International Journal of Transla-tional Medicine, 4(3), 463-485.